CAMBRIDGE, Mass.--(

马萨诸塞州剑桥--(

BUSINESS WIRE

商业热线

)--MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced the in-licensing of a next-generation selective PARP1 (poly ADP-ribose polymerase) inhibitor, now known as MOMA-989. The company also provided an update on the clinical progress of Polθ inhibitor MOMA-313 and outlined the clinical path for Werner inhibitor MOMA-341..

)--MOMA Therapeutics是一家发现和开发新一代精确治疗药物的临床阶段生物制药公司，今天宣布了下一代选择性PARP1（聚ADP-核糖聚合酶）抑制剂（现称为MOMA-989）的许可证。该公司还提供了Polθ抑制剂MOMA-313临床进展的最新信息，并概述了Werner抑制剂MOMA-341的临床路径。。

“The addition of this selective PARP1 inhibitor to our portfolio solidifies our lead asset focus on the DNA damage response,” said Asit Parikh, M.D., Ph.D., chief executive officer of MOMA. “Our conviction in the potential for achieving practice-changing efficacy by combining MOMA-989 with our Polθ inhibitor catalyzed the licensing deal.

MOMA首席执行官Asit Parikh医学博士说：“在我们的投资组合中加入这种选择性PARP1抑制剂，巩固了我们对DNA损伤反应的主要资产关注。”。“我们坚信通过将MOMA-989与我们的Polθ抑制剂结合起来，可以实现改变实践效果的潜力，这促进了许可协议的达成。

It puts MOMA in position to generate multiple impactful clinical datasets across three thematically linked assets over the next two years.”.

它使MOMA能够在未来两年内跨越三个主题相关的资产生成多个有影响力的临床数据集。”。

MOMA-989: Selective PARP1 inhibitor

MOMA-989：选择性PARP1抑制剂

MOMA-989 is an oral, highly potent, brain-penetrant development candidate with a potentially best-in-class compound profile. Under the terms of the exclusive license agreement with a U.S.-based biopharmaceutical partner, MOMA receives global rights to MOMA-989 and assumes responsibility for all further research, development and commercialization of the asset and related follow-on molecules..

MOMA-989是一种口服，高效，脑渗透剂开发候选者，具有潜在的同类最佳化合物特征。根据与美国生物制药合作伙伴的独家许可协议条款，MOMA获得MOMA-989的全球权利，并承担资产和相关后续分子的所有进一步研究、开发和商业化的责任。。

Selective targeting of PARP1 has demonstrated significant potential for patients with tumors displaying homologous recombination deficiency (HRD). MOMA anticipates filing an IND with the U.S. FDA by the end of 2025. The company plans to develop MOMA-989 for patients with HRD, both as single agent and as part of a mechanistically synergistic combination with MOMA-313.

PARP1的选择性靶向已证明对显示同源重组缺陷（HRD）的肿瘤患者具有显着潜力。MOMA预计在2025年底之前向美国FDA提交IND。该公司计划为HRD患者开发MOMA-989，既可以作为单一药物，也可以作为与MOMA-313机械协同组合的一部分。

Following successful IND clearance, early single agent efficacy data is anticipated in the second half of 2026..

成功清除IND后，预计2026年下半年将有早期单药疗效数据。。

MOMA-313: Polθ helicase inhibitor

MOMA-313:Polθ解旋酶抑制剂

MOMA-313 is a potentially best-in-class, highly potent and selective Polθ helicase inhibitor with a favorable emerging safety profile. This profile lends MOMA-313 to broad combinability with other targeted agents including antibody drug conjugates, radioligand therapeutics, PARP inhibitors, and select chemotherapies.

MOMA-313是一种潜在的同类最佳，高效和选择性的Polθ解旋酶抑制剂，具有良好的新兴安全性。该概况使MOMA-313与其他靶向药物具有广泛的可组合性，包括抗体-药物偶联物，放射性配体治疗剂，PARP抑制剂和选择性化学疗法。

Preclinical data demonstrate that combining a PARP inhibitor with a Polθ inhibitor in tumors harboring alterations in HRD has unique potential to deepen and prolong therapeutic responses..

临床前数据表明，在HRD改变的肿瘤中，将PARP抑制剂与Polθ抑制剂联合使用具有独特的潜力，可以加深和延长治疗反应。。

MOMA-313 is currently in a Phase 1a dose escalation study designed to evaluate its potential as monotherapy and in combination with olaparib, an approved, non-selective PARP inhibitor (NCT06545942). An initial readout of olaparib combination efficacy data is anticipated in mid-2026, with development of the proprietary combination with MOMA-989 to initiate in late 2026..

MOMA-313目前正在进行1a期剂量递增研究，旨在评估其作为单一疗法的潜力，并与经批准的非选择性PARP抑制剂olaparib（NCT06545942）联合使用。奥拉帕尼联合疗效数据的初步读数预计在2026年年中，与MOMA-989的专有组合的开发将于2026年底启动。。

MOMA-341: Werner helicase inhibitor

MOMA-341：Werner解旋酶抑制剂

The company remains on track to file an IND for MOMA-341 during the first quarter of 2025. MOMA-341 is a highly differentiated oral, potent and selective, covalent Werner helicase inhibitor with a novel chemical scaffold that was identified via the company’s KNOMATIC

该公司仍将在2025年第一季度为MOMA-341提交IND。MOMA-341是一种高度分化的口服，强效和选择性共价Werner解旋酶抑制剂，具有通过该公司的KNOMATIC鉴定的新型化学支架

TM

TM公司

platform. The company plans to assess the potential of MOMA-341 as a treatment for patients with cancers demonstrating microsatellite instability (MSI-H). Following successful IND clearance, MOMA anticipates an initial readout of early single agent efficacy data in mid-2026.

平台。该公司计划评估MOMA-341作为治疗表现出微卫星不稳定性（MSI-H）的癌症患者的潜力。在成功清除IND后，MOMA预计将在2026年年中初步读出早期单药疗效数据。

About MOMA Therapeutics

关于MOMA Therapeutics

MOMA Therapeutics is a clinical-stage, next-generation precision medicine company dedicated to targeting highly dynamic proteins that underlie human disease via an oral, small molecule approach, utilizing its proprietary KNOMATIC

MOMA Therapeutics是一家临床阶段的下一代精准医学公司，致力于利用其专有的KNOMATIC，通过口服小分子方法靶向构成人类疾病基础的高度动态蛋白质

TM

TM公司

platform. The platform is designed to exploit key vulnerabilities inherent to all dynamic proteins, namely their dependence on well-coordinated, stepwise changes in protein conformation. By focusing on genetically validated targets with high translation potential, MOMA is rapidly advancing its pipeline toward responses in the clinic.

平台。该平台旨在利用所有动态蛋白质固有的关键漏洞，即它们依赖于蛋白质构象的良好协调，逐步变化。通过专注于具有高翻译潜力的基因验证目标，MOMA正在迅速推进其在临床上的反应管道。

MOMA has existing discovery partnerships with Roche and Bayer, as well as a wholly owned pipeline. For more information on MOMA, go to .

MOMA与罗氏和拜耳现有发现合作伙伴关系，以及全资管道。有关MOMA的更多信息，请访问。

www.momatx.com

www.momatx.com

.

.